Prasco Signs Distribution, Supply Agreement With Axcan Pharma
Prasco to market the authorized generic versions of URSO Forte Scored and URSO 250
Prasco has entered into a distribution and supply agreement with Axcan for authorized generic versions of URSO 250 and URSO Forte Scored family of products.
Prasco plans to market both the authorized generic versions in the US.
URSO 250 and URSO Forte Scored are approved by FDA for the treatment of patients with Primary Biliary Cirrhosis (PBC).
Thomas Arington, CEO of Prasco, said: “We are pleased to provide Ursodiol Tablets 250mg and 500mg to pharmacists and consumers. As a Prasco Authorized Generic, Ursodiol Tablets will provide patients with the identical experience as the brand product.”
Ursodiol Tablets 500mg and Ursodiol Tablets 250mg are AB-rated, therapeutically equivalent and substitutable for the brand, URSO Forte Scored and URSO 250, respectively.
Related Insight
Suppliers Directory
Alliance Life Sciences Consulting Group, Inc. – Management and Technology Consulting Experts
Alliance Life Sciences Consulting Group, Inc. is a management and technology consultancy with a proven track record of working with many Life Sciences clients to successfully define, deploy and support business critical applications.
Suppliers
Nycomed - Contract Services
Nycomed is a privately owned global mid-sized pharmaceutical company with a differentiated portfolio focused on branded medicines in the areas of gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.
Suppliers
Random42 - Medical Animation
Random42 is the world’s premier medical animation company. Over the past 20 years we have created over 150 mechanism-of-action (MoA) animations for the world's leading pharmaceutical and biotechnology companies and won over 50 industry awards.
Suppliers
Bioceros - Pre-Clinical Development of Monoclonal Antibodies and Generation of GMP-Ready Proteins
Bioceros is one of Europe's premier providers of services in pre-clinical development of monoclonal antibodies and generation of GMP-ready protein producing cell lines.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
MyQUMAS 2011
Published by QUMAS
White Papers
QbD with Gerteis Dry Granulation Technology
Published by Gerteis
White Papers
The Pulse on Recruitment--Recruiting patients on TV and radio
Published by CenterWatch
White Papers
Reversed-Phase Analysis of Alkylbenzene Sulfonates
Published by Tosoh Bioscience
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.